Bill Summary & Status for the 106th Congress

NEW SEARCH | HOME | HELP
H.R.2700
Sponsor: Rep Jackson, Jesse L., Jr. (introduced 8/4/1999)
Latest Major Action: 9/1/1999 Referred to House subcommittee
Title: To require that United States supported clinical research that is conducted in sub-Saharan African countries be conducted in accordance with the most protective ethical standards regarding the use of human research subjects, and to prohibit the revocation or revision of intellectual property or competition laws or policies of sub-Saharan African countries that are designed to promote access to pharmaceuticals or other medical technologies.
Jump to: Titles, Status, Committees, Related Bill Details, Amendments, Cosponsors, Summary
TITLE(S):  (italics indicate a title for a portion of a bill)
STATUS: (color indicates Senate actions)
8/4/1999:
Referred to the House Committee on International Relations.
9/1/1999:
Referred to the Subcommittee on International Economic Policy and Trade.
9/1/1999:
Referred to the Subcommittee on Africa.
COMMITTEE(S):
RELATED BILL DETAILS:

***NONE***

AMENDMENT(S):

***NONE***

COSPONSORS(8), ALPHABETICAL [followed by Cosponsors withdrawn]:     (Sort: by date)

Rep Barrett, Thomas M. - 9/8/1999 Rep Brown, Sherrod - 9/8/1999
Rep Davis, Danny K. - 2/10/2000 Rep Kucinich, Dennis J. - 9/8/1999
Rep Nadler, Jerrold - 8/5/1999 Rep Owens, Major R. - 9/8/1999
Rep Sanders, Bernard - 8/5/1999 Rep Schakowsky, Janice D. - 9/8/1999

SUMMARY AS OF:
8/4/1999--Introduced.

Highly Essential Lifesaving Pharmaceuticals for Africa Act (HELP for Africa Act) - Prohibits the use of funds appropriated to any Federal department or agency: (1) for the conduct of clinical research in a sub-Saharan African country unless specified conditions are met; or (2) to seek, through negotiation or otherwise, the revocation or revision of any intellectual property or competition law or policy of a sub-Saharan African country that is designed to promote access to pharmaceuticals or other medical technologies, if such law or policy complies with the Agreement on Trade-Related Aspects of Intellectual Property Rights.